CTOs on the Move

Viridian Therapeutics

www.viridianbio.com

 
Viridian Therapeutics focuses in advancing new treatments for patients with diseases that are underserved by today`s therapies.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Viridian Therapeutics raised $27M on 09/29/2020

Similar Companies

iCo Therapeutics

iCo Therapeutics Inc. is a Vancouver-based development company focused on in-licensing drugs with clinical history redosing or reformulating for new or expanded indications. iCo has exclusive worldwide rights to three products. iCo-007, a second generation antisense candidate licensed from Isis Pharmaceuticals, is currently in a Phase I trial in Diabetic Macular Edema patients with compelling early data. iCo-008 is a human monoclonal antibody targeting eotaxin-1 with Phase II clinical history, licensed from AstraZeneca/MedImmune. iCo-009 is a proprietary oral formulation of amphotericin B licensed from the University of British Columbia.

GeneGo bioinformatics software

GeneGo bioinformatics software is a Saint Joseph, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cell Biosciences Inc

Cell Biosciences Inc is a Santa Clara, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Transave

Transave is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CARsgen

CARsgen is a biopharmaceutical company with operations in China and the U.S. focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors. The company has built an integrated cell therapy platform with in-house capabilities that span target discovery, antibody development, clinical trials, and commercial-scale manufacturing. CARsgen has internally developed novel technologies and a product pipeline with global rights to address major challenges of CAR T-cell therapies, such as improving the safety profile, enhancing the efficacy in treating solid tumors, and reducing treatment costs. Our vision is to become a global biopharmaceutical leader that brings innovative and differentiated cell therapies to cancer patients worldwide and makes cancer curable.